NEW YORK, March 29, 2026, 12:07 EDT
- CSL Limited closed at $24.34 in U.S. trading on Friday, gaining 1.16%.
- CSL disclosed in its most recent buyback report that it snapped up 89,271 shares on March 26, bringing the cumulative tally to nearly 5.18 million.
- Investors are digesting the 81% plunge in first-half profit announced in February, with management sticking to its full-year outlook.
CSL Limited’s American depositary receipts closed Friday at $24.34, gaining 1.16%. After a period marked by earnings troubles and a change at the top, the Australian biotech’s U.S.-listed shares finally showed a hint of steadiness.
This isn’t some obscure stock—CSL ranks among Australia’s biggest healthcare players. But faith in the company took a knock back in February, after an 81% plunge in first-half reported profit. The group bumped its buyback up to US$750 million and brought in Gordon Naylor as interim chief following Paul McKenzie’s retirement.
Plasma therapies, flu vaccines, kidney and iron medications—this company’s reach covers them all. About 325 plasma collection centers anchor its network across the United States, Europe, and China. If there’s a slip-up operationally, it doesn’t take long for mood and shares to react.
CSL’s latest filing shows the company picked up 89,271 of its own shares on March 26, paying out A$12.81 million for that batch. So far, CSL has bought back 5,180,698 shares altogether, spending roughly A$900.4 million through the on-market scheme, which is due to wrap up June 30.
CSL’s half-year numbers left Chief Financial Officer Ken Lim admitting the result fell short. “Clearly not satisfied with our performance,” Lim said, though he pointed to “an ambitious growth plan” aimed at the second half. Immunoglobulin—a key plasma-based immune therapy—heads the list, along with albumin and a slate of newer product launches.
Naylor kept a similar tone, insisting to analysts he was “not prepared to accept” that the company couldn’t push harder, despite calling the U.S. vaccine market “extraordinarily difficult.” David Tuckwell, chief investment officer at ETF Shares, described Naylor’s return as “an attempt to calm nerves”—and maybe also “a salvage mission.” Reuters
Still, risks remain clear. Seqirus, according to CSL, is set for a weaker second half as flu vaccine sales drop off seasonally, and last year’s avian flu boost won’t come back. Over at Vifor, generic rivals keep the pressure on. Behring faces its own headaches, with U.S. Medicare adjustments and shifting policies in China cutting into performance.
Peers aren’t sitting still. Last week, Spanish plasma group Grifols signed off on an IPO for a minority slice of its U.S. biopharma arm, aiming to drum up cash, cut debt, and fuel investments. Back in February, the company said it was looking for core earnings to climb more than 25% this year.
CSL’s buyback signals robust balance-sheet health, but the tougher issue remains. Full-year targets are holding, yet some divisions continue to face challenges. The stock’s next move looks set to hinge more on signs of real improvement in operations than on financial maneuvers.
